BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Autoimmunity
,
Doxorubicin
,
rs2230926
,
TGFB1
,
Coagulation
,
Pseudomonas infection
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Soft tissue sarcomas
Summary
General Info
Curated Studies
Most Correlated Studies
Ewing sarcoma cells with HOTAIR knockdown and mesenchymal stem cells with HOTAIR overexpression
Soft tissue sarcomas
Effect of 5-AZA on Ewing Sarcoma cell lines A673, SK-ES-1 and SK-N-MC
Ewing sarcoma cells with MYBL2 siRNA knockdown
Ewing sarcoma A-673 cells treated with the Jumonji-domain histone demethylase inhibitor JIB-04
Explore Curated Studies Results
Literature
Most Relevant Literature
Antiangiogenic approach in soft-tissue sarcomas.
Planned preservation surgery for soft tissue sarcomas adjacent to critical structures.
Elicitation of health state utilities in soft tissue sarcoma.
Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry.
Head and neck soft tissue sarcoma].
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
Stereotactic Radiosurgery for Soft Tissue Sarcoma
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ